Anti CV2/CRMP5 antibody paraneoplastic syndrome: clinical features
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Anti CV2/CRMP5 antibody paraneoplastic syndrome: clinical features. Small cell lung cancer (SCLC), Thymoma. Fully referenced neurology checklist.
Typical associated tumours
- Small cell lung cancer (SCLC)
- Thymoma
Other associated tumours
Locked: subscribe to see this section.
Encephalitic features
Locked: subscribe to see this section.
Movement disorders
Locked: subscribe to see this section.
Ophthalmic features
Locked: subscribe to see this section.
Peripheral neuropathy (PN)
Locked: subscribe to see this section.
Other clinical features
Locked: subscribe to see this section.
Acronym
Locked: subscribe to see this section.
References
- De Beukelaar JW, Smitt PAS. Managing paraneoplastic neurological disorders. Oncologist 2006; 11:292-305.
- Graus F, Delattre JY, Antoine, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. JNNP 2004; 75:1235-1240.
- Helgason VÞ, Qureshi PAAA, Bollineni VR, Þórarinsson BL, Arkink EB. Anti-CV2/collapsin response mediator protein 5 (CRMP5) paraneoplastic encephalitis induced by small cell lung cancer. Cureus 2023; 15:e34323.
- Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54:38-50.
- Jarius S, Wandinger KP, Borowski K, Stoecker W, Wildemann B. Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 2012; 114:331-335.
- And 22 more. Subscribe to see the full list
